Biogen

In News

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease - Biogen

Biogen - May 08, 2026

Biogen Stock On Fire: Up 6.6% With 7-Day Winning Streak - Trefis

Trefis - May 13, 2026

Biogen Stock Rockets 6.6% With 7-Day Winning Streak - Trefis

Trefis - May 13, 2026

Biogen to Report First Quarter 2026 Financial Results April 29, 2026 - Biogen

Biogen - Apr 29, 2026

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region - Biogen

Biogen - Apr 20, 2026

Biogen to acquire Apellis for $5.6bn - Financier Worldwide

Financier Worldwide - May 12, 2026

Is Biogen Inc. (BIIB) one of the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen? - Yahoo Finance

Yahoo Finance - May 12, 2026

Eisai, Biogen Receive Extended FDA Review for Lecanemab Subcutaneous Starting Dose - BioPharm International

BioPharm International - May 08, 2026

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology - Biogen

Biogen - Mar 31, 2026

Should FDA’s LEQEMBI IQLIK Review Delay Reshape How Biogen (BIIB) Investors View Alzheimer’s Strategy? - simplywall.st

simplywall.st - May 11, 2026

Eisai, Biogen face delay to subcutaneous Leqembi - pharmaphorum

pharmaphorum - May 08, 2026

Biogen beats profit expectations as demand for newer rare-disease drugs fuel growth - Reuters

Reuters - Apr 29, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment